Abstract Number: 2010 • ACR Convergence 2023
B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a chronic disease of the airways. It is mainly caused by smoking. Active smoking is a risk factor…Abstract Number: 0617 • ACR Convergence 2023
Pulmonary Rehabilitation in Connective Tissue Disease-Related Interstitial Lung Diseases
Background/Purpose: Interstitial lung disease (ILD) is a common manifestation of connective tissue disease (CTD)1. Pulmonary rehabilitation (PR) can be utilized to improve dyspnea and quality…Abstract Number: 1588 • ACR Convergence 2023
Monocyte-derived Macrophages Accumulate in the Lungs in anti-MDA5+ Dermatomyositis with RP-ILD: Proinflammatory and Profibrotic Phenotype Revealed by Single-cell RNA Sequencing
Background/Purpose: Anti-melanoma differentiation-associated gene 5-positive dermatomyositis (anti-MDA5+ DM) is a rare inflammatory autoimmune disease with impressively life-threatening rapid progressive interstitial lung disease (RP-ILD). The mechanism…Abstract Number: 2173 • ACR Convergence 2023
Window of Opportunity in the Treatment of Rheumatoid Arthritis-Interstitial Lung Disease with Abatacept. National Multicenter Study of 509 Patients
Background/Purpose: Interstitial lung disease (ILD) is a severe complication of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in the treatment of RA-ILD, especially if…Abstract Number: 0622 • ACR Convergence 2023
The Effectiveness of Breath-holding Test to Predict Pulmonary Function in Systemic Sclerosis Patients Using Machine Learning Model
Background/Purpose: Pulmonary involvement is major causes of mortality in patients with systemic sclerosis (SSc). The breath-holding test (BHT), rapid bedside test, is a useful surrogate…Abstract Number: 1666 • ACR Convergence 2023
TNF-mediated Pulmonary Hypertension Is Marked by Aberrant Bone Morphogenic Protein (BMP) and Integrin/Basement Membrane Ligand-Receptor Signaling
Background/Purpose: : We recently described TNF-transgenic mice as a novel model of pulmonary hypertension (PH) and have shown that they express altered endothelial and mesenchymal…Abstract Number: 2188 • ACR Convergence 2023
Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis
Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…Abstract Number: 0634 • ACR Convergence 2023
Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study
Background/Purpose: Anaemia in systemic sclerosis (SSc) is under-studied and under-characterised. Its prevalence amongst SSc patients is not well described, nor are its effects on outcomes…Abstract Number: 1699 • ACR Convergence 2023
Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis
Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…Abstract Number: 2193 • ACR Convergence 2023
Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement
Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…Abstract Number: 0637 • ACR Convergence 2023
Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort
Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…Abstract Number: 1701 • ACR Convergence 2023
Treatment Regimens and Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in Light of the 2022 ESC/ERS Guidelines
Background/Purpose: The 2022 ESC/ERS Guidelines recommend upfront combination therapy for low- and intermediate-risk, and triple therapy for high-risk patients with systemic sclerosis (SSc)-associated pulmonary arterial…Abstract Number: 2353 • ACR Convergence 2023
Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…Abstract Number: 0638 • ACR Convergence 2023
Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)
Background/Purpose: Pulmonary arterial hypertension (PAH) patients can be stratified as low, intermediate, or high risk of 1-year mortality based on clinical, biochemical and haemodynamic prognostic…Abstract Number: 1704 • ACR Convergence 2023
Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 12
- Next Page »